Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension

Arthritis and Rheumatism

Volumn 65, Issue 12, 2013, Pages 3194-3201

  Khanna, Dinesh ^a,b   Gladue, Heather ^a,b   Channick, Richard ^c   Chung, Lorinda ^d,e   Distler, Oliver ^f   Furst, Daniel E ^g   Hachulla, Eric ^h   Humbert, Marc ⁱ   Langleben, David ^j   Mathai, Stephen C ^k   Saggar, Rajeev ^l   Visovatti, Scott ^b   Altorok, Nezam ^b   Townsend, Whitney ^b   Fitzgerald, John ^g   McLaughlin, Vallerie V ^b  

^a EMORY UNIVERSITY   (United States)

^b Division of Rheumatology   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^f UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIV LILLE   (France)

ⁱ UNIVERSITÉ PARIS SACLAY   (France)

^j MCGILL UNIVERSITY   (Canada)

^k JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; CARBON MONOXIDE;

ARTICLE; BREATH ANALYSIS; CONNECTIVE TISSUE DISEASE; DISEASE ASSOCIATION; HUMAN; LUNG FUNCTION TEST; MIXED CONNECTIVE TISSUE DISEASE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SCLERODERMA; SCREENING TEST; SYSTEMATIC REVIEW; SYSTEMIC SCLEROSIS; TRANSTHORACIC ECHOCARDIOGRAPHY;

CONNECTIVE TISSUE DISEASES; CONSENSUS; EARLY DIAGNOSIS; HUMANS; HYPERTENSION, PULMONARY; PROGNOSIS;

EID: 84888793944     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.38172     Document Type: Article

References (51)

1. Mukerjee D, St George D, Knight C, Davar J, Wells AU, Du Bois RM, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology (Oxford) 2004; 43: 461-6.
2. Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D, et al. Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. Arthritis Rheum 2011; 63: 3522-30.
3. Burdt MA, Hoffman RW, Deutscher SL, Wang GS, Johnson JC, Sharp GC,. Long-term outcome in mixed connective tissue disease: longitudinal clinical and serologic findings. Arthritis Rheum 1999; 42: 899-909.
4. Ruiz-Irastorza G, Garmendia M, Villar I, Egurbide MV, Aguirre C,. Pulmonary hypertension in systemic lupus erythematosus: prevalence, predictors and diagnostic strategy. Autoimmun Rev 2013; 12: 410-5.
5. Udayakumar N, Venkatesan S, Rajendiran C,. Pulmonary hypertension in rheumatoid arthritis-relation with the duration of the disease. Int J Cardiol 2008; 127: 410-2.
6. Condliffe R, Kiely DG, Peacock AJ, Corris PA, Gibbs JS, Vrapi F, et al. Connective tissue disease-associated pulmonary arterial hypertension in the modern treatment era. Am J Respir Crit Care Med 2009; 179: 151-7.
7. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension Association. J Am Coll Cardiol 2009; 53: 1573-619.
8. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, et al, Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-63.
9. Badesch DB, Champion HC, Sanchez MA, Hoeper MM, Loyd JE, Manes A, et al. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009; 54: S55-66.
10. Fitch K, Bernstein SJ, Aguilar MS, Burnand B, LaCalle JR, Lazaro P, et al. The RAND/UCLA appropriateness method user's manual. Santa Monica (CA): RAND Corporation; 2001.
11. Khanna D, Khanna PP, FitzGerald JD, Singh MK, Bae S, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 2. Therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken) 2012; 64: 1447-61.
12. Khanna D, FitzGerald JD, Khanna PP, Bae S, Singh MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1. Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012; 64: 1431-46.
13. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis [published erratum appears in Arthritis Care Res (Hoboken) 2012;64:464]. Arthritis Care Res (Hoboken) 2010; 62: 1515-26.
14. Saag KG, Teng GG, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59: 762-84.
15. Gladue H, Altorok N, Townsend W, McLaughlin V, Khanna D,. Screening and diagnostic modalities for connective tissue disease-associated pulmonary arterial hypertension: a systematic review. Semin Arthritis Rheum 2013. E-pub 9/10/13.
16. Whiting P, Rutjes AW, Reitsma JB, Bossuyt PM, Kleijnen J,. The development of QUADAS: a tool for the quality assessment of studies of diagnostic accuracy included in systematic reviews. BMC Med Res Methodol 2003; 3: 25.
17. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011; 155: 529-36.
18. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, et al, GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490.
19. Schunemann HJ, Oxman AD, Brozek J, Glasziou P, Jaeschke R, Vist GE, et al, GRADE Working Group. Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ 2008; 336: 1106-10.
20. National Conference on chronic disease. Public Health Nurs 1951; 43: 344.
21. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23: 581-90.
22. Alarcon-Segovia D, Villareal M,. Classification and diagnostic criteria for mixed connective tissue disease. In:, Kasukawa R, Sharp G, editors. Mixed connective tissue disease and anti-nuclear antibodies. Amsterdam: Elsevier; 1987. p. 33-40.
23. Sharp GC, Irvin WS, Tan EM, Gould RG, Holman HR,. Mixed connective tissue disease-an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). Am J Med 1972; 52: 148-59.
24. Kahn MF, Appelboom T,. Syndrom de Sharp. In:, Kahn MF, Peltier AP, Meyer O, Piette JC, editors. Les maladies systemiques. 3rd ed. Paris: Flammarion; 1991. p. 545-556.
25. Kasukawa R, Tojo T, Miyawaki S,. Preliminary diagnostic criteria for classification of mixed connective tissue disease. In:, Kasukawa R, Sharp GC, editors. Mixed connective tissue disease and anti-nuclear antibodies. Amsterdam: Elsevier; 1987. p. 41-8.
26. Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, et al, and the ItinerAIR-Sclerodermie Study Group. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum 2009; 60: 1831-9.
27. Yoshida S,. Pulmonary arterial hypertension in connective tissue diseases. Allergol Int 2011; 60: 405-9.
28. Hoeper MM,. Definition, classification, and epidemiology of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009; 30: 369-75.
29. Tunariu N, Gibbs SJ, Win Z, Gin-Sing W, Graham A, Gishen P, et al. Ventilation-perfusion scintigraphy is more sensitive than multidetector CTPA in detecting chronic thromboembolic pulmonary disease as a treatable cause of pulmonary hypertension. J Nucl Med 2007; 48: 680-4.
30. Coghlan JG, Denton CP, Grunig E, Bonderman D, Distler O, Khanna D, et al, on behalf of the DETECT Study Group. Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. Ann Rheum Dis 2013. E-pub ahead of print.
31. Montani D, Savale L, Natali D, Jais X, Herve P, Garcia G, et al. Long-term response to calcium-channel blockers in non-idiopathic pulmonary arterial hypertension. Eur Heart J 2010; 31: 1898-907.
32. Saggar R, Khanna D, Furst DE, Shapiro S, Maranian P, Belperio JA, et al. Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities. Arthritis Rheum 2010; 62: 3741-50.
33. Bae S, Saggar R, Bolster MB, Chung L, Csuka ME, Derk C, et al, for the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Investigators. Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis-results from the PHAROS registry. Ann Rheum Dis 2012; 71: 1335-42.
34. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007; 66: 754-63.
35. Launay D, Hachulla E, Hatron PY, Jais X, Simonneau G, Humbert M,. Pulmonary arterial hypertension: a rare complication of primary Sjögren's syndrome: report of 9 new cases and review of the literature. Medicine (Baltimore) 2007; 86: 299-315.
36. Humbert M, Gerry Coghlan J, Khanna D,. Early detection and management of pulmonary arterial hypertension. Eur Respir Rev 2012; 21: 306-12.
37. The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston: Little Brown; 1994. p. 253-6.
38. Rajaram S, Swift AJ, Capener D, Elliot CA, Condliffe R, Davies C, et al. Comparison of the diagnostic utility of cardiac magnetic resonance imaging, computed tomography, and echocardiography in assessment of suspected pulmonary arterial hypertension in patients with connective tissue disease. J Rheumatol 2012; 39: 1265-74.
39. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr,. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986; 29: 515-24.
40. Allanore Y, Borderie D, Avouac J, Zerkak D, Meune C, Hachulla E, et al. High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis. Arthritis Rheum 2008; 58: 284-91.
41. Thakkar V, Stevens WM, Prior D, Moore OA, Byron J, Liew D, et al. N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. Arthritis Res Ther 2012; 14: R143.
42. Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J, et al. Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum 2005; 52: 3792-800.
43. Meune C, Avouac J, Airo P, Beretta L, Dieude P, Wahbi K, et al. Prediction of pulmonary hypertension related to systemic sclerosis by an index based on simple clinical observations. Arthritis Rheum 2011; 63: 2790-6.
44. Gladue H, Steen V, Allanore Y, Saggar R, Saggar R, Maranian P, et al. Combination of echocardiographic and pulmonary function test measures improves sensitivity for the diagnosis of systemic sclerosis-associated pulmonary arterial hypertension: analysis of two cohorts. J Rheumatol 2013. E-pub 8/21/13.
45. Phung S, Strange G, Chung LP, Leong J, Dalton B, Roddy J, et al. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis. Intern Med J 2009; 39: 682-91.
46. Ciurzynski M, Bienias P, Irzyk K, Rymarczyk Z, Kostrubiec M, Lichodziejewska B, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension in patients with systemic sclerosis. Eur Heart J 2010; 31: 869-70.
47. Jansa P, Becvar R, Ambroz D, Palecek T, Tomcik M, Skacelova S, et al. Pulmonary arterial hypertension associated with systemic sclerosis in the Czech Republic. Clin Rheumatol 2012; 31: 557-61.
48. Avouac J, Airo P, Meune C, Beretta L, Dieude P, Caramaschi P, et al. Prevalence of pulmonary hypertension in systemic sclerosis in European Caucasians and metaanalysis of 5 studies. J Rheumatol 2010; 37: 2290-8.
49. Rudski LG, Lai WW, Afilalo J, Hua L, Handschumacher MD, Chandrasekaran K, et al. Guidelines for the echocardiographic assessment of the right heart in adults: a report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography. J Am Soc Echocardiogr 2010; 23: 685-713.
50. Nair R, Aggarwal R, Khanna D,. Methods of formal consensus in classification/diagnostic criteria and guideline development. Semin Arthritis Rheum 2011; 41: 95-105.
51. Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625-39.